220 related articles for article (PubMed ID: 29733427)
1. Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer.
Hesham HM; Lasheen DS; Abouzid KAM
Med Res Rev; 2018 Sep; 38(6):2058-2109. PubMed ID: 29733427
[TBL] [Abstract][Full Text] [Related]
2. Anticancer properties of chimeric HDAC and kinase inhibitors.
Biersack B; Polat S; Höpfner M
Semin Cancer Biol; 2022 Aug; 83():472-486. PubMed ID: 33189849
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.
Amin SA; Adhikari N; Jha T
Future Med Chem; 2017 Dec; 9(18):2211-2237. PubMed ID: 29182018
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
Zhao C; Dong H; Xu Q; Zhang Y
Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
[No Abstract] [Full Text] [Related]
5. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
7. The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.
Stiborová M; Eckschlager T; Poljaková J; Hraběta J; Adam V; Kizek R; Frei E
Curr Med Chem; 2012; 19(25):4218-38. PubMed ID: 22680633
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Bass AKA; El-Zoghbi MS; Nageeb EM; Mohamed MFA; Badr M; Abuo-Rahma GEA
Eur J Med Chem; 2021 Jan; 209():112904. PubMed ID: 33077264
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
10. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Adhikari N; Amin SA; Jha T
Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
[TBL] [Abstract][Full Text] [Related]
11. Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
Seo SY
Arch Pharm Res; 2012 Feb; 35(2):197-200. PubMed ID: 22370774
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Mottamal M; Zheng S; Huang TL; Wang G
Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
14. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
15. An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present).
Liu YM; Liou JP
Expert Opin Ther Pat; 2023; 33(5):349-369. PubMed ID: 37249104
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.
Wang T; Sepulveda M; Gonzales P; Gately S
Bioorg Med Chem Lett; 2013 Sep; 23(17):4790-3. PubMed ID: 23906422
[TBL] [Abstract][Full Text] [Related]
17. Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents.
Cincinelli R; Musso L; Artali R; Guglielmi MB; La Porta I; Melito C; Colelli F; Cardile F; Signorino G; Fucci A; Frusciante M; Pisano C; Dallavalle S
PLoS One; 2018; 13(10):e0205018. PubMed ID: 30300374
[TBL] [Abstract][Full Text] [Related]
18. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
19. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
